[go: up one dir, main page]

PE20231504A1 - Anticuerpos especificos para kras y sus usos - Google Patents

Anticuerpos especificos para kras y sus usos

Info

Publication number
PE20231504A1
PE20231504A1 PE2022002496A PE2022002496A PE20231504A1 PE 20231504 A1 PE20231504 A1 PE 20231504A1 PE 2022002496 A PE2022002496 A PE 2022002496A PE 2022002496 A PE2022002496 A PE 2022002496A PE 20231504 A1 PE20231504 A1 PE 20231504A1
Authority
PE
Peru
Prior art keywords
kras
cdr
seq
amino acid
acid sequence
Prior art date
Application number
PE2022002496A
Other languages
English (en)
Inventor
Melinda M Mulvihill
John Gerard Quinn
Micah Steffek
Weiru Wang
John Bruning
Christopher Williamson Davies
Marie Evangelista
James Thomas Koerber
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20231504A1 publication Critical patent/PE20231504A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Referida a un anticuerpo aislado o fragmento de union al antigeno de este que se une a KRas humano, en donde el anticuerpo se une especificamente al KRas unido a GDP (KRasGDP) con una mayor afinidad que al KRas unido a GTP (KRas-GTP), donde el anticuerpo comprende (a) una region variable de la cadena liviana que comprende: (i) CDR-L1 que comprende la secuencia de aminoacidos SGSSSNIGSNYVY (SEQ ID NO:9); (ii) CDR-L2 que comprende la secuencia de aminoacidos RNNQRPS (SEQ ID NO:10); (iii) CDR-L3 que comprende la secuencia de aminoacidos AAWDERLSGWV (SEQ ID NO:11); y (b) una region variable de la cadena pesada que comprende: (i) CDR-H1 que comprende la secuencia de aminoacidos SSNWWS (SEQ ID NO:12); (ii) CDR-H2 que comprende la secuencia de aminoacidos EIYHSGSTNYNPSLKS (SEQ ID NO:13); y (iii) CDR-H3 que comprende la secuencia de aminoacidos GSSSWYDLGPFDY (SEQ ID NO:14). Tambien se refiere a metodos para cribar inhibidores de KRas y metodos para medir la union de KRas a los anticuerpos descritos en la presente.
PE2022002496A 2020-04-30 2021-04-28 Anticuerpos especificos para kras y sus usos PE20231504A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018356P 2020-04-30 2020-04-30
PCT/US2021/029517 WO2021222333A1 (en) 2020-04-30 2021-04-28 Kras specific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20231504A1 true PE20231504A1 (es) 2023-09-26

Family

ID=75977821

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002496A PE20231504A1 (es) 2020-04-30 2021-04-28 Anticuerpos especificos para kras y sus usos

Country Status (14)

Country Link
US (1) US20220112308A1 (es)
EP (1) EP4143237A1 (es)
JP (1) JP2023524041A (es)
KR (1) KR20230002598A (es)
CN (1) CN115461375A (es)
AU (1) AU2021263767A1 (es)
BR (1) BR112022022021A2 (es)
CA (1) CA3174692A1 (es)
CR (1) CR20220598A (es)
IL (1) IL297672A (es)
MX (1) MX2022013310A (es)
PE (1) PE20231504A1 (es)
TW (1) TW202204420A (es)
WO (1) WO2021222333A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4448526A1 (en) 2021-12-17 2024-10-23 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
IL317823A (en) 2022-06-30 2025-02-01 Lilly Co Eli KRAS G12C inhibitor for cancer treatment
CN116640218B (zh) * 2023-06-01 2024-06-04 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种靶向kras g12v单链抗体片段、嵌合抗原受体car及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (es) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
FR2046920B1 (es) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6248537B1 (en) * 1999-05-28 2001-06-19 Institut Pasteur Use of the combing process for the identification of DNA origins of replication
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
TWI452135B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) * 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
BR112019012263A2 (pt) * 2016-12-15 2020-01-28 Univ California composições e métodos para tratar câncer
WO2019107812A1 (ko) * 2017-11-16 2019-06-06 오름테라퓨틱 주식회사 세포의 세포질에 침투하여 세포내 활성화된 ras를 억제하는 항체 및 이의 용도

Also Published As

Publication number Publication date
WO2021222333A1 (en) 2021-11-04
BR112022022021A2 (pt) 2022-12-13
AU2021263767A1 (en) 2022-09-08
US20220112308A1 (en) 2022-04-14
CA3174692A1 (en) 2021-11-04
TW202204420A (zh) 2022-02-01
MX2022013310A (es) 2022-11-14
CR20220598A (es) 2023-01-17
IL297672A (en) 2022-12-01
KR20230002598A (ko) 2023-01-05
EP4143237A1 (en) 2023-03-08
JP2023524041A (ja) 2023-06-08
CN115461375A (zh) 2022-12-09

Similar Documents

Publication Publication Date Title
PE20231504A1 (es) Anticuerpos especificos para kras y sus usos
ES2523740T3 (es) Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
PE20211709A1 (es) Anticuerpos que reconocen tau
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
RS54197B1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
CU20210073A7 (es) Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
MY200988A (en) CD3 Binding Antibodies
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
NZ596042A (en) Humanized anti-factor d antibodies
NZ585559A (en) Humanized antibodies against tl1a
MX2018014714A (es) Composiciones para inhibir la activacion del complemento dependiente de la masp-2.
PE20121817A1 (es) Anticuerpos antagonistas anti-notch3
CO6311009A2 (es) Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu
RS53405B (en) Humanized anti cxcr4 antibodies for the treatment of cancer
AR078796A1 (es) Composiciones y metodos para tratar trastornos inflamatorios
CL2024003412A1 (es) Anticuerpos anti-tl1a y métodos de uso de los mismos
RU2018106456A (ru) Антитело к epha4
AR126758A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
PE20230844A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos
AR124558A1 (es) Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco
CO6180454A2 (es) Anticuerpos de la egfl7 y metodos de uso
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
PE20231680A1 (es) Anticuerpos anti-cd30l y usos de estos
PE20231953A1 (es) Anticuerpos multiespecificos y combinaciones de anticuerpos